Evotec receives $2.9 million grant for drug safety research
The Gates Foundation has awarded Evotec a three-year grant to utilize human stem cell technology to predict fetal development risks in early-stage drug development.
Evotec has secured a $2.9 million grant from the Bill & Melinda Gates Foundation to advance its drug safety testing capabilities. The three-year project focuses on refining human stem cell-based platforms to identify potential risks to fetal development early in the drug discovery process.
The initiative expands upon a 2023 project aimed at providing global health researchers with more accurate data regarding the safety profiles of novel drug candidates. By utilizing stem cell models, the company aims to better predict how new chemical compounds interact with human biology during developmental stages.
This research is intended to assist in the early filtering of pharmaceutical candidates, potentially reducing the development of substances that pose reproductive risks. The funding will support ongoing efforts to integrate these predictive models into standard drug discovery workflows.